title: PIP5K1α inhibition as a therapeutic strategy for prostate cancer.
authors.affiliation: Department of Microbiology, Immunology, and Molecular Genetics, jdrake@mednet.ucla.edu jiaotihuang@mednet.ucla.edu.
authors.forename: Justin M
authors.initials: JM
authors.lastname: Drake
authors.affiliation: Jonsson Comprehensive Cancer Center, and Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095 jdrake@mednet.ucla.edu jiaotihuang@mednet.ucla.edu.
authors.forename: Jiaoti
authors.initials: J
authors.lastname: Huang
mesh_terms: D000818:Animals; D054659:Diketopiperazines / Q000494:pharmacology*; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology*
chemical_list: D054659:Diketopiperazines; C000592937:ISA-2011B; D007211:Indoles; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; C014843:1,2,3,4-tetrahydroisoquinoline; D017853:Phosphotransferases (Alcohol Group Acceptor); C020077:1-phosphatidylinositol-4-phosphate 5-kinase